Page 119 - Merck Sharp News Today

Recent studies have shown PPIs can cause significant gut microbiota changes, which could lead to its impact on cancer immunotherapy. Image: Pexels A

Belzutifan might serve as an alternative for or a complement to surgery Belzutifan (MK-6482), a novel oral agent that targets germline pathogenic variants in the von Hippel-Lindau (VHL) gene that gives rise to VHL disease, demonstrated robust clinical activity and a very mild adverse event (AE) profile in VHL patients with renal cell carcinoma, a

Covid-19 antiviral pills show promise, but experts warn they are unlikely to be available to help as the virus spreads through traffic-light New Zealand.

Dementia Discovery Fund spinout LoQus23 Therapeutics announced the closing of a $15.4M seed fund, which the Cambridge-based company plans to use to develop drug candidates to target Huntington's disease and other triplet repeat disorders.

Swissmedic has approved the extension of Covid-19 boosters to all people 16 years of age and over for the Pfizer/BioNTech vaccine.

Swissmedic has approved the extension of Covid-19 boosters to all people 16 years of age and over for the Pfizer/BioNTech vaccine.

This video series and advertorial are fully funded and developed by MSD. Click the following links for prescribing information for Keytruda®

Pfizer claims its antiviral pill 89% effective in high-risk COVID-19 cases - Know how it works - Pfizer said the patients taking the drug along with another antiviral had an 89% reduction in their combined rate of hospitalisation or death.

U.S. pharmaceutical company Pfizer has developed a COVID pill noting that it reduces the risk of severe COVID cases by 89 percent, according to the clinical trials of the company.

Antiviral drugs can help your body fight off viruses like COVID-19. Learn more about forms of antivirals approved for COVID-19 treatment.